Welcome to our dedicated page for Collegium Pharmaceutical news (Ticker: COLL), a resource for investors and traders seeking the latest updates and insights on Collegium Pharmaceutical stock.
Collegium Pharmaceutical, Inc. reports developments for a diversified biopharmaceutical business focused on commercial medicines for serious medical conditions. Its recurring news centers on JORNAY PM for ADHD, a neuropsychiatry growth business, and a responsible pain management portfolio that includes BELBUCA, Xtampza ER, Nucynta products and Symproic.
Company updates also cover operating and financial results, investor presentations, real-world data from pain medications, branded ADHD awareness campaigns, capital deployment, credit facilities, material agreements, shareholder voting matters and governance disclosures.
Collegium Pharmaceutical, a leader in responsible pain management, announced its participation in upcoming investor conferences. Management will attend the Jefferies London Healthcare Conference with virtual one-on-one meetings on November 18, 2021, and the Piper Sandler Annual Healthcare Conference featuring a virtual fireside chat on December 1, 2021. The fireside chat will be accessible via the Investor section of their website, with a replay available for 30 days post-event. For more information, visit Collegium's website.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced its participation in two upcoming investor conferences. The Jefferies London Healthcare Conference will host virtual one-on-one meetings on November 18, 2021. Additionally, the Piper Sandler Annual Healthcare Conference 2021 will feature a virtual fireside chat on December 1, 2021. The fireside chat will be webcast, and a replay will be available on the company's Investor section website for 30 days following the event.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) reported a net income of $8.0 million and adjusted EBITDA of $37.3 million for Q3 2021. The company's Board has authorized a $25 million accelerated share repurchase, part of a broader $100 million initiative. Collegium aims for record full-year revenue and profits, driven by a strong pain management portfolio. Xtampza ER reached a 32.5% market share in ER oxycodone, while the Nucynta franchise exceeded $150 million in revenue. The company updated its 2021 financial guidance, adjusting Xtampza ER expected revenues down to $130-$135 million.
Collegium Pharmaceutical (Nasdaq: COLL) will host a conference call and live webcast on November 4, 2021, at 4:30 p.m. ET to discuss its Q3 2021 financial results and provide a corporate update. Investors can join the call by dialing (877) 407-8037 for U.S. participants or (201) 689-8037 for international callers, referencing the "Collegium Pharmaceutical Q3 2021 Earnings Call." The webcast will be available on the company's website for replay shortly after the event.
Collegium Pharmaceutical (Nasdaq: COLL) presented four poster sessions at the Annual PAINWeek National Conference, emphasizing its commitment to responsible pain management.
The presentations focused on the misuse and abuse of its products, particularly XTAMPZA® ER and Nucynta®, and provided real-world data on their diversion and non-medical use.
These efforts highlight the company's dedication to scientific research and education among healthcare providers, reinforcing its position in the pain management sector.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced participation in two upcoming investor conferences in September 2021. The H.C. Wainwright 23rd Annual Global Investment Conference will feature a fireside chat on September 13, 2021, from 7:00 to 7:30 AM Eastern Time. Additionally, Collegium will present at the Cantor Virtual Global Healthcare Conference on September 28, 2021, from 8:00 to 8:30 AM Eastern Time. Both presentations will be accessible via the company's investor website, with replays available for 30 days post-event.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced a $100 million share repurchase program, reflecting confidence in its growth and pain management portfolio. CEO Joe Ciaffoni emphasized their solid financial position and commitment to disciplined capital allocation. The program allows management flexibility in repurchasing shares based on market conditions and business needs, which could enhance shareholder value over time.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) reported strong financial results for Q2 2021, with net income of $72.8 million and adjusted EBITDA of $40.1 million. Xtampza® ER achieved a market share of 31.5% in the oxycodone extended-release market, marking a significant growth from 30.6% in March 2021. However, the company adjusted its revenue guidance downwards for Xtampza ER to $140.0-$150.0 million, while increasing guidance for the Nucynta Franchise to $195.0-$205.0 million. A conference call is scheduled for today at 4:30 p.m. ET to discuss these results further.
Collegium Pharmaceutical (Nasdaq: COLL) will host a conference call on August 5, 2021, at 4:30 PM ET to discuss its financial results and corporate updates. Investors can participate by dialing (877) 407-8037 for U.S. callers or (201) 689-8037 for international participants. A live webcast will be available on the company's website, with a replay accessible approximately two hours post-event. Collegium is committed to responsible pain management and operates from Stoughton, Massachusetts.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced the publication of a study titled, “Nonmedical Use of Xtampza® ER and Other Oxycodone Medications in Adults Evaluated for Substance Abuse Treatment,” in the Journal of Pain Research. The study emphasizes the importance of monitoring real-world data on the abuse and misuse of its products. Richard Malamut, M.D., highlighted the need for the medical community to access these data to make informed treatment decisions. However, the study underscores that Xtampza ER still carries a high potential for addiction, abuse, and misuse.